MEDLINE Journals

    Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.

    Authors
    Sahi J, Milad MA, Zheng X, et al. 
    Institution

    Department of Pharmacokinetics, Pfizer Global Research and Development, Ann Arbor MI 48105, USA. jasminder.sahi@pfizer.com

    Source
    J Pharmacol Exp Ther 2003 Sep; 306(3) :1027-34.
    Abstract

    In vitro and clinical studies were conducted to characterize the potential of avasimibe, an acyl-CoA/cholesterol acyltransferase inhibitor to cause drug-drug interactions. Clinically, 3- and 6-fold increases in midazolam (CYP3A4 substrate) oral clearance were observed after 50 and 750 mg of avasimibe daily for 7 days, respectively. A 40% decrease in digoxin (P-glycoprotein substrate) area under the curve was observed with 750 mg of avasimibe daily for 10 days. In vitro studies were conducted to define the mechanisms of these interactions. Induction was observed in CYP3A4 activity and immunoreactive protein (EC50 of 200-400 nM) in primary human hepatocytes treated with avasimibe. Rifampin treatment yielded similar results. Microarray analysis revealed avasimibe (1 microM) increased CYP3A4 mRNA 20-fold, compared with a 23-fold increase with 50 microM rifampin. Avasimibe induced P-glycoprotein mRNA by about 2-fold and immunoreactive protein in a dose-dependent manner. Transient transfection assays showed that avasimibe is a potent activator of the human pregnane X receptor (hPXR) and more active than rifampin on an equimolar basis. Drug-drug interaction studies for CYP3A4 using pooled human hepatic microsomes and avasimibe at various concentrations, revealed IC50 values of 20.7, 1.6, and 3.1 microM using testosterone, midazolam, and felodipine as probe substrates, respectively. Our results indicate that avasimibe causes clinically significant drug-drug interactions through direct activation of hPXR and the subsequent induction of its target genes CYP3A4 and multiple drug resistance protein 1.

    Mesh
    Acetates
    Cytochrome P-450 CYP3A
    Cytochrome P-450 Enzyme System
    Digoxin
    Drug Interactions
    Enzyme Induction
    Enzyme Inhibitors
    Gene Expression
    Hepatocytes
    Humans
    Microsomes, Liver
    Midazolam
    P-Glycoprotein
    RNA, Messenger
    Receptors, Cytoplasmic and Nuclear
    Receptors, Steroid
    Sulfonic Acids
    Language

    eng

    Pub Type(s)
    Journal Article
    PubMed ID

    12766253

    Content Manager
    Related Content

    Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.

    Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo.

    Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.

    Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate.

    Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor.

    MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.

    In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.

    Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators.